Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Synthetic Anti-infective Drugs >  Antiviral drugs >  Lopinavir

Lopinavir

Basic information Safety Related Supplier
Lopinavir Basic information
Lopinavir Chemical Properties
  • Melting point:124-127°C
  • Boiling point:924.1±65.0 °C(Predicted)
  • Density 1.163±0.06 g/cm3(Predicted)
  • storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
  • solubility DMSO: soluble20mg/mL, clear
  • form powder
  • pka13.89±0.46(Predicted)
  • color white to beige
  • optical activity[α]/D -20 to -27°, c = 0.4 in methanol
  • Stability:Hygroscopic
  • CAS DataBase Reference192725-17-0(CAS DataBase Reference)
Safety Information
  • RIDADR 3077
  • HS Code 29335990
Lopinavir Usage And Synthesis
  • DescriptionLopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action. Ritonavir inhibits the P450 isoenzyme CYP3A4 and the human liver microsomal metabolism of lopinavir, so strongly amplifying plasma levels of this latter component. In AIDS patients, the plasma HIV RNA level was considerably reduced and the CD4+ T-cell counts increased after administration of lopinavir combined with relatively small doses of ritonavir. Kaletra is intended to be used jointly with other antiretroviral agents.
  • Chemical PropertiesWhite Crystalline Solid
  • OriginatorAbbott (US)
  • UsesA selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral.
  • UsesLopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM
  • DefinitionChEBI: A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3- ethyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.
  • IndicationsLopinavir is available in the United States only as a fixed-dose combination with ritonavir (Kaletra). In this regimen, a low dose of ritonavir is used to inhibit the rapid inactivation of lopinavir by CYP3A4.
  • brand nameKaletra
  • Antimicrobial activityLopinavir is active against HIV-1 and HIV-2.
  • Acquired resistanceSignificant resistance to the antiretroviral efficacy of ritonavirbooted lopinavir occurs as a result of amino acid substitutions at positions 32, 47 and 82 in the protease region. Protease inhibitor resistance is uncommon in patients identified with early failure of combination therapy with ritonavir boostedlopinavir and nucleotide reverse transcriptase inhibitors.
  • General DescriptionLopinavir is a protease inhibitor that has been approved foruse in combination with ritonavir for patients with HIV whohave not responded to other treatment modalities. Lopinaviris used in excess over ritonavir. Ritonavir at amounts givenhas no antiretroviral activity, Ritonavir inhibits lopinavir’smetabolism by CYP3A4, causing a higher level of lopinavirin the system. The combination is the first protease inhibitorapproved for patients as young as 6 months of age.
  • Pharmaceutical ApplicationsA synthetic compound, co-formulated with ritonavir for oral administration. In this formulation, ritonavir functions to inhibit the metabolic clearance of lopinavir, and does not contribute to the antiretroviral activity.
  • PharmacokineticsOral absorption: Not known/available
    Cmax 400 mg + ritonavir 100 mg twice daily: c. 9.6 mg/L
    Cmin 400 mg + ritonavir 100 mg twice daily: c. 5.5 mg/L
    Plasma half-life: c. 5–6 h
    Volume of distribution: Not known/available
    Plasma protein binding: c. 98–99%
    Absorption and distribution
    The absorption of lopinavir–ritonavir in capsule or liquid form is favorably affected by the presence of food, particularly if high in fat. The CNS penetration is good. It has a semen:plasma ratio of 0.07. It is distributed into breast milk.
    Metabolism
    Lopinavir is extensively metabolized by the CYP3A4 system, but this is inhibited by ritonavir.
    Excretion
    Over an 8-day period after single dosing with the combined formulation, around 10% and 83% of the administered dose is recovered in urine and feces, respectively. Less than 3% of the dose is recovered as unchanged drug in urine and 20% in feces. In mild to moderate hepatic impairment, an increase in exposure of approximately 30% is observed, but is probably not clinically relevant. It should be avoided in severe hepatic impairment.
  • Clinical UseTreatment of HIV infection (in combination with ritonavir and other antiretroviral agents)
  • Side effectsThe most common adverse events seen in trials of complex antiretroviral regimens were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted lopinavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.
  • Side effectsSide effects, which are generally mild, include diarrhea, nausea, asthenia, and headache. Pancreatitis occurs rarely. Ritonavir is a potent inhibitor of CYP3A4 and also inhibits CYP2D6. In addition to the drugs contraindicated for all protease inhibitors, flecainide, propafenone, pimozide, and rifampin should not be given with lopinavir–ritonavir combination therapy.
Lopinavir(192725-17-0)Related Product Information
LopinavirSupplierMore
  • Company Name:Wisdom Drugs Co., Ltd. Gold
  • Tel:13961212855 0519-85138993-
  • Email:1736768490@qq.com
  •  
  • Company Name:Taizhou Crene Biotechnology Co. Ltd. Gold
  • Tel:13396860566
  • Email:sales@pharm-intermediates.com
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  •  
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Email:jkinfo@jkchemical.com;market6@jkchemical.com
  •  
  • Company Name:3B Pharmachem (Wuhan) International Co.,Ltd.
  • Tel:18930552037 821-50328103-801
  • Email:3bsc@sina.com
  •